SCHEMBL4649014

SCHEMBL4649014

O=C(O)C(=Cc1ccccc1)OC(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.47
AKR1C1 Q04828 1/20 0.46
CYP2C9 P11712 2/20 0.42
CYP3A4 P08684 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.40
HTT P42858 2/20 0.40
ALDH1A1 P00352 3/20 0.38
TSHR P16473 1/20 0.38
ABCG2 Q9UNQ0 1/20 0.38
RECQL P46063 2/20 0.37
MCL1 Q07820 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CYP1A1 P04798 1/20 0.37
MAOB P27338 1/20 0.37
CYP1B1 Q16678 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153123 1.00 AKR1C3 (0.47) AKR1C3AKR1C1CYP2C9CYP3A4MEN1
SCHEMBL4649011 1.00 AKR1C3 (0.47) AKR1C3AKR1C1CYP2C9CYP3A4MEN1
SCHEMBL7149422 0.85 MCL1 (0.46) AKR1C3AKR1C1CYP2C9CYP3A4MEN1
SCHEMBL7149424 0.85 MCL1 (0.46) AKR1C3AKR1C1CYP2C9CYP3A4MEN1
SCHEMBL7615069 0.83 AKR1C3 (0.50) AKR1C3AKR1C1CYP2C9CYP3A4MEN1
SCHEMBL28723296 0.82 MEN1 (0.44) AKR1C3MEN1KMT2AABCG2RECQL
SCHEMBL17311133 0.82 MEN1 (0.44) AKR1C3AKR1C1CYP2C9CYP3A4MEN1
SCHEMBL4725824 0.81 MEN1 (0.42) AKR1C3AKR1C1MEN1KMT2AHTT
SCHEMBL4725821 0.81 MEN1 (0.42) AKR1C3AKR1C1MEN1KMT2AHTT
SCHEMBL6553166 0.78 AKR1C3 (0.52) AKR1C3AKR1C1CYP2C9CYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114204120-B Electrolyte for adapting silicon-carbon cathode of lithium ion battery and application of electrolyte 华南师范大学 2024-04-19 CN disclosed
EP-1948623-A2 HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES Janssen Pharmaceutica, N.V. (BE) 2008-07-30 EP disclosed
WO-2007041077-A2 HETEROCYCLIC AMIDE DERIVATIVES AS RXR AGONISTS FOR THE TREATMENT OF DYSLIPIDEMIA, HYPERCHOLESTEROLEMIA AND DIABETES JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-12 WO disclosed
EP-1309590-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS Pharmacia Italia S.p.A. (IT) 2003-05-14 EP disclosed
WO-2001098299-A1 AZAINDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2001-12-27 WO disclosed
EP-1045833-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER INC. (US) 2000-10-25 EP disclosed
WO-1999035130-A1 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS PFIZER PHARMACEUTICALS INC. (JP) 1999-07-15 WO disclosed